🧬 Prenatal Genetic Screening Panel Comparison Simulator

Two Categories of Prenatal Genetic Testing — Screening Estimates Risk, Diagnosis Confirms It

Prenatal genetic testing for aneuploidy (trisomy 21, 18, 13, and sex chromosome abnormalities) is divided into two categories with fundamentally different purposes. Screening tests — combined first-trimester screening, the quad screen, and cell-free DNA (cfDNA/NIPT) — estimate the probability that a fetus is affected, without any procedure-related risk to the pregnancy. Diagnostic tests — chorionic villus sampling (CVS) and amniocentesis — sample fetal genetic material directly and yield a near-definitive karyotype, at the cost of a small, quantifiable risk of pregnancy loss. Professional guidelines (ACOG, SMFM) recommend that both screening AND diagnostic testing be discussed and offered to every pregnant patient, regardless of age or baseline risk.

• 5: Modalities compared (3 screening + 2 diagnostic)
• T21, T18, T13: Conditions targeted (plus sex chromosome aneuploidy)
• 100%: Recommended offer rate (ACOG: offer to all patients)
• Karyotype/microarray: Diagnostic confirmation (the only definitive result)

Why the screening/diagnostic distinction matters clinically

Screening and diagnostic tests answer different clinical questions, and conflating them is one of the most common sources of patient confusion and downstream anxiety:

Screening tests (combined, quad, cfDNA): • Report a risk estimate — e.g., "1 in 4,500" or "high risk" — not a yes/no answer • No procedure-related risk to the pregnancy; blood draw or ultrasound only • A "positive" or "high-risk" screen result is NOT a diagnosis; it changes the pretest probability and should prompt an offer of diagnostic testing • A "negative" or "low-risk" screen substantially lowers but does not eliminate risk — screening tests are not 100% sensitive • Performance is described using detection rate (sensitivity) and false-positive rate, evaluated against a specific condition (most commonly trisomy 21)

Diagnostic tests (CVS, amniocentesis): • Directly sample fetal (placental or amniotic fluid) cells and analyze the full karyotype or chromosomal microarray • Provide a definitive answer — detection rate for aneuploidy exceeds 99.9% • Carry a small, procedure-related risk of pregnancy loss (historically quoted ~0.1–0.3% in experienced hands, lower than earlier literature suggested) • Also detect conditions that no screening test can identify — balanced translocations, deletions/duplications below cfDNA resolution, and single-gene disorders when paired with targeted molecular testing

A critical counseling point: cfDNA, despite very high sensitivity and specificity for the common trisomies, remains a SCREENING test. A high-risk cfDNA result should be confirmed with diagnostic testing before any irreversible decision is made, because of the possibility of a false positive (e.g., confined placental mosaicism, vanishing twin, maternal copy-number variants, or maternal malignancy).

Detection rate, false-positive rate, and positive predictive value

Three statistics govern how a test result should be interpreted, and they behave differently:

• Detection rate (sensitivity): the proportion of affected pregnancies correctly flagged as high-risk/abnormal. cfDNA detection for trisomy 21 approaches 99%; combined first-trimester screening approaches 85%; the quad screen approaches 81%. • False-positive rate: the proportion of unaffected pregnancies incorrectly flagged as high-risk. Combined and quad screens run false-positive rates near 5%; cfDNA runs closer to 0.1–0.5%, dramatically reducing unnecessary downstream diagnostic procedures. • Positive predictive value (PPV): the probability that a positive result reflects a truly affected fetus. PPV depends heavily on baseline (pretest) prevalence — the same test has a much higher PPV in a 42-year-old patient than in a 22-year-old patient, because the affected fraction of positives increases as baseline prevalence rises. This is why cfDNA PPV, while excellent in older patients, can be surprisingly modest in a low-risk 20-something with a positive result for a rare condition.

These differences explain why cfDNA has largely supplanted the traditional serum/ultrasound screens as first-line for patients who present early enough and can access it, while combined and quad screening remain essential tools where cfDNA access, cost, or timing is limiting, and because the traditional screens (unlike most cfDNA panels) also flag risk for open neural tube defects (via MSAFP) and provide early structural information (via nuchal translucency).

Combined First-Trimester, Quad Screen, and cfDNA — Three Windows Into Risk

Each screening modality operates in a different gestational window and combines different biological signals. Combined first-trimester screening pairs an 11–13.9 week nuchal translucency ultrasound measurement with two serum analytes (PAPP-A and free β-hCG). The quad screen, performed 15–22 weeks, measures four serum analytes and additionally screens for open neural tube defects. cfDNA analyzes cell-free placental DNA fragments shed into maternal plasma and can be drawn from 10 weeks through the remainder of pregnancy, offering the highest detection rate of any screening test for the common trisomies.

• 11–13.9 wk: Combined screen window (requires NT ultrasound expertise)
• 15–22 wk: Quad screen window (also screens for open NTDs)
• ~4%: cfDNA fetal fraction min. (below this, result is uninterpretable)
• ~99%: cfDNA detection (T21) (highest of the screening tests)

Combined first-trimester screening — nuchal translucency and serum analytes

Combined screening integrates three measurements obtained between 11 weeks 0 days and 13 weeks 6 days:

• Nuchal translucency (NT): ultrasound measurement of the fluid-filled space at the back of the fetal neck; increased NT is associated with aneuploidy and also with congenital cardiac defects and other structural anomalies, independent of chromosomal status. Requires credentialed sonographer measurement (NTQR/FMF certification) for reliability. • PAPP-A (pregnancy-associated plasma protein A): typically low in trisomy 21 and trisomy 18/13; very low PAPP-A is also an independent marker for later placental insufficiency, growth restriction, and preeclampsia risk. • Free β-hCG: typically elevated in trisomy 21, low in trisomy 18/13.

Advantages: early result allows earlier decision-making and, if desired, first-trimester CVS as follow-up; increased NT itself provides useful structural information regardless of karyotype. Limitation: 5% false-positive rate means 1 in 20 unaffected pregnancies screens positive; does not screen for open neural tube defects (no MSAFP component).

Quad screen and cfDNA — second-trimester serum panel and cell-free DNA

Quad screen (15–22 weeks, optimal 16–18 weeks): • Four analytes: maternal serum AFP (alpha-fetoprotein), hCG, unconjugated estriol, and inhibin-A • Uniquely also screens for open neural tube defects and ventral wall defects via elevated MSAFP • Useful for patients presenting too late for first-trimester screening, or as a second-tier option • Detection rate ~81% for trisomy 21 at a 5% false-positive rate

cfDNA / Non-invasive prenatal testing (NIPT), from ~10 weeks onward: • Analyzes fragments of cell-free DNA in maternal plasma, the majority derived from apoptotic placental trophoblast (not the fetus directly) — an important nuance, since placental and fetal karyotype occasionally differ (confined placental mosaicism) • Requires adequate "fetal fraction" (placental-derived fraction of total cfDNA, typically needs >4%); fetal fraction is lower with higher maternal weight/BMI, very early gestational age, and some fetal aneuploidies themselves, which can result in a "no-call" requiring redraw or alternative testing • Detects trisomy 21, 18, 13, and optionally sex chromosome aneuploidies; expanded panels can screen for select microdeletions, though performance for these is less robust and less validated • Detection rate ~99%, false-positive rate ~0.1–0.5% for trisomy 21 — the best performance characteristics among screening tests, and the reason many societies now endorse offering cfDNA as a first-line option to all patients, not only those at elevated risk

CVS and Amniocentesis — Direct Sampling for a Definitive Karyotype

When a definitive answer is required — because of a high-risk screen, a structural anomaly on ultrasound, a strong family history, or simply patient preference for certainty — chorionic villus sampling and amniocentesis provide direct access to fetal genetic material. Both are image-guided outpatient procedures with a well-characterized, low risk of pregnancy loss that must be weighed against the value of a definitive result.

• 10.5–13.9 wk: CVS window (transabdominal or transcervical)
• ≥15 wk: Amniocentesis window (transabdominal, ultrasound-guided)
• ~0.1–0.3%: Procedure-related loss risk (modern series, experienced operators)
• >99.9%: Diagnostic accuracy (full karyotype/microarray)

Chorionic villus sampling — early diagnostic access via placental tissue

CVS obtains a small sample of chorionic villi (placental tissue of trophoblastic origin) via a transabdominal or transcervical approach under continuous ultrasound guidance, typically between 10 weeks 5 days and 13 weeks 6 days of gestation (earlier sampling is avoided due to historical association with limb reduction defects).

Advantages: earliest possible diagnostic result, allowing earlier decision-making and, if desired, first-trimester management options. Yields full karyotype, chromosomal microarray, and can be extended to single-gene testing when indicated (e.g., known familial mutation).

Key pitfall — confined placental mosaicism (CPM): because CVS samples placental tissue, a discordant result between placenta and fetus occurs in roughly 1–2% of cases. A mosaic or abnormal CVS result may require confirmatory amniocentesis before acting on the result. This is a core counseling point distinguishing CVS from amniocentesis, where the sample (amniocytes) is fetal in origin.

Amniocentesis — second-trimester fluid-based diagnostic sampling

Amniocentesis involves transabdominal, ultrasound-guided aspiration of a small volume of amniotic fluid (containing desquamated fetal cells), typically performed from 15 weeks of gestation onward (mid-trimester amniocentesis, 15–20 weeks, is standard; earlier "early amniocentesis" before 14 weeks is avoided due to higher loss and talipes rates).

Advantages: amniocytes are fetal in origin (not placental), avoiding the confined placental mosaicism issue seen with CVS; also permits AFP and acetylcholinesterase measurement in fluid, useful adjuncts for open neural tube defect detection. Widely available later in pregnancy for patients presenting after the CVS window has closed, or when follow-up of an abnormal second-trimester screen or ultrasound finding is needed.

Both procedures: performed under continuous ultrasound guidance by experienced operators, use of Rh(D) immune globulin in Rh-negative unsensitized patients, and same-day discussion of results turnaround (rapid FISH/QF-PCR results in 24–48 hours for the common aneuploidies, full karyotype in 7–14 days, microarray in 5–10 days).

Modern procedure-related loss risk estimates for both CVS and amniocentesis, when performed by experienced operators under ultrasound guidance, are substantially lower than the historically quoted 1 in 200–300 — contemporary large cohort studies suggest a procedure-attributable risk closer to 0.1–0.3%, and some estimates suggest the excess risk over baseline pregnancy loss may be even smaller. This evolving evidence should be discussed transparently during counseling.

Choosing a Pathway — Patient Values, Risk Category, and Shared Decision-Making

There is no single "correct" test for every patient. The optimal pathway integrates the patient's baseline (a priori) risk, gestational age at presentation, desire for early versus later information, tolerance for procedure-related risk, and what she would do with a result. ACOG and SMFM guidance is explicit: every patient, regardless of age or risk factors, should be offered both screening and diagnostic testing options and supported in choosing — or declining — testing altogether.

• Universal: Recommended offer scope (age alone no longer restricts options)
• Both valid: Stepwise vs. simultaneous (depends on patient preference/timing)
• Diagnostic testing: Positive screen next step (confirm before irreversible decisions)
• Optional: Testing is (patient may decline all testing)

Patient counseling — autonomy, values, and informed choice

Pretest counseling should cover, in accessible language: what each test can and cannot tell you, the difference between screening and diagnosis, turnaround time, the possibility of incidental or uncertain findings (variants of uncertain significance, secondary findings, non-paternity), and — critically — what the patient would do with each possible result. A patient who would not pursue pregnancy termination or early intervention regardless of result may still value information for delivery planning, or may reasonably decline testing altogether; testing is always optional and declining it is a legitimate choice that should be supported without judgment.

Stepwise vs. simultaneous strategies: • Stepwise (sequential): screening first, diagnostic testing reserved for positive/high-risk screens — minimizes unnecessary procedures and their associated risk, at the cost of a delayed definitive answer • Simultaneous/direct-to-diagnostic: appropriate when a patient has a strong reason for wanting definitive information regardless of screening result (e.g., prior affected pregnancy, known parental balanced translocation, strong anxiety, ultrasound anomaly already identified), or simply prefers certainty and accepts the procedural risk upfront

Cost and access considerations: cfDNA, while performing best, may carry higher out-of-pocket cost or more limited insurance coverage than serum-based screening in some settings; diagnostic testing requires access to a center with maternal-fetal medicine/genetics expertise. These practical factors are legitimate parts of shared decision-making, not just clinical performance statistics.

Professional society guidance and the current recommended default

Both ACOG and SMFM currently recommend that all pregnant patients, regardless of maternal age or baseline risk, be offered the choice of aneuploidy screening OR diagnostic testing — the older paradigm of reserving diagnostic testing for "advanced maternal age" (historically ≥35 years) has been superseded by a risk-informed, patient-centered approach. Maternal age remains one input into the prior probability calculation, but is no longer used as a rigid eligibility gate.

Practical synthesis used in this simulator: • Average risk, no other factors: any screening test is a reasonable first-line option; cfDNA offers the best performance where accessible, but combined/quad screening remain valid and are preferred by some patients or systems • Advanced maternal age: cfDNA's higher detection rate and lower false-positive rate are particularly advantageous as baseline prevalence rises; diagnostic testing should still be actively offered, not merely available on request • Positive/high-risk prior screen: diagnostic testing (CVS if still within window, otherwise amniocentesis) is the recommended next step to confirm before any irreversible decision • Prior affected pregnancy or known familial genetic risk: many patients in this situation prefer to proceed directly to diagnostic testing given the higher prior probability and the value of a definitive answer; genetic counseling referral is strongly recommended in this scenario

The single most important counseling message across all risk categories: a screening test result is a probability, not a diagnosis, and every patient — not only those historically labeled "high risk" — has the right to be offered the full range of screening and diagnostic options and to make the choice that fits her own values.